The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•11 March 2026•

1 min read

FDA Accuses uniQure of Data Manipulation for AMT-130; Legal Investigation Intensifies

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The FDA reportedly accused uniQure of pushing distorted and manipulated data for its AMT-130 drug.

The U.S. Food and Drug Administration (FDA) has reportedly accused biotechnology firm uniQure of presenting distorted and manipulated clinical data regarding its AMT-130 drug. Following these allegations, the law firm Hagens Berman announced an update to its ongoing securities class action investigation against the company. Federal officials issued a public rebuke, characterizing the AMT-130 product as a failure despite the company's previous representations to the market. The accusations suggest a significant breach of scientific integrity and potential efforts to mislead investors about the drug's true efficacy. This development poses a severe threat to uniQure’s market valuation and future regulatory prospects, as investor trust faces a sharp decline. Legal pressure continues to mount as shareholders seek accountability for the alleged misconduct.